Business Wire

Echosens Appoints Medical Equipment Expert Jo Massoels as Chief Marketing Officer, Expands Global Marketing of FibroScan to Halt Liver Disease Epidemic

Share

Echosens, a high-technology company offering the FibroScan family of products, announces the appointment of Jo Massoels as chief marketing officer, bringing to Echosens significant expertise in the medical equipment sector that will be leveraged to expand the market development strategy for the FibroScan suite of products and services. In this position, which includes oversight of medical affairs and support for physicians in the assessment and management of patients with chronic liver disease, Massoels draws upon his experience as former vice president, Global Marketing & Solutions, at Dentsply Sirona, a leading dental equipment and supplies manufacturing company.

Dominique Legros, Group CEO, Echosens, welcomes Massoels to the leadership team, saying, “Jo has a successful track record for developing business opportunities and transforming digital operations, and he will play a key role in defining and implementing strategies that propel us toward new levels of global success. In collaboration with general management and all departments of the Company, Jo will guide the realization of our vision to support physicians in their assessment and management of patients with chronic liver diseases, design direct strategic marketing programs and provide in-depth technical insight and an entrepreneurial mindset to extend our worldwide footprint.”

While at Dentsply Sirona, Massoels served in additional roles, including director of Digital Implant Solutions, general manager and Business Unit manager. Prior to this, he served as business unit director at Materialise and service and project manager at Franz Haniel & Cie. GmbH. He holds several international patents next to a Master of Science degree and an executive MBA.

Massoels states, “This is a unique opportunity to help reverse the impact of the global liver disease epidemic, which accounts for approximately 2 million deaths per year worldwide. I am passionate about the Echosens mission to raise awareness around the importance of non-invasive testing to detect and monitor liver diseases and the corporate commitment to empowering medical professionals with the best tools to assess and manage liver health.”

About Echosens

Pioneer in its field, Echosens significantly changed the practice of liver diagnosis with FibroScan®, the non-invasive gold standard solution for comprehensive management of liver health. FibroScan® is recognized worldwide as the reference for non-invasive liver fibrosis and liver steatosis assessment with more than 2,500+ peer reviewed publications and 60+ international guidelines recommendations. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide.

Contact information

Brittany Tedesco
CPR Communications
btedesco@cpronline.com
201.641.1911 x 14

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Effissimo Releases Presentation Explaining Proposal to Appoint Independent Investigators at Toshiba1.3.2021 10:00:00 EETPress release

Effissimo Capital Management (“Effissimo”), the largest shareholder of Toshiba Corporation (“Toshiba”) (TYO:6502) through the funds it manages, today released a presentation explaining the reasons behind its proposal for an independent investigation into reported irregularities surrounding Toshiba’s July 2020 Annual General Meeting of Shareholders (“AGM”). Effissimo’s proposal will be voted on by Toshiba’s shareholders at an extraordinary shareholders meeting scheduled for March 18, 2021. The full proposal in English can be found here. Supplementing its letter to shareholders dated February 24, 2021, Effissimo’s presentation explains its proposal for an independent investigation into the irregular handling of shareholder voting and shareholder pressure at the closely contested AGM, which Toshiba’s conflicted Audit Committee’s self-audit fails to address. The presentation provides data showing discrepancies in the claimed delivery times of mailed ballots said by Toshiba’s vote tabulator

Mobidiag sai CE-IVD-merkinnän korona-, influenssa A-, influenssa B- ja RS-viruksen tunnistavalle Amplidiag® RESP-4 -testilleen1.3.2021 09:00:00 EETTiedote

Mobidiag Oy on saanut CE-IVD-merkinnän Amplidiag® RESP-4-molekyylidiagnostiikkatestilleen, jolla pystytään nopeasti tunnistamaan yhdellä kertaa yleisimmät hengitystieinfektioita aiheuttavat virukset SARS-CoV-2 (koronavirus), influenssa A, influenssa B ja RSV. Kyseiset virukset aiheuttavat samankaltaisia oireita, joten lääkäreiden ei ole helppo päätellä, mikä virus potilaalla on. Amplidiag® RESP-4 -testillä virus pystytään määrittämään nopeasti ja luotettavasti yhdestä nenänielunäytteestä, mikä helpottaa oikean hoitopäätöksen tekemistä. Testi tehdään Mobidiagin Amplidiag® Easy -laitteistolla, jonka etuja ovat optimoitu näyteseulontaprosessi sekä automaattinen DNA/RNA:n eristys ja PCR-levyn valmistelu. Laitteisto perustuu vakiintuneeseen korkean suorituskyvyn PCR-tekniikkaan ja pystyy käsittelemään 46 näytettä noin kolmessa tunnissa. Uusi testi laajentaa entisestään Mobidiagin diagnostiikkatestivalikoimaa. Mobidiagin toimitusjohtaja Tuomas Tenkanen: ”Olemme erittäin tyytyväisiä saatuamme

CLH Evolves to Exolum, the Company’s New Global Brand1.3.2021 08:00:00 EETPress release

Exolum is the new brand name chosen by the CLH Group from now on to face its ambitious objectives for the future, focused on adapting its business to decarbonisation and the energy transition, the digitalisation of its activities and the fight against climate change. This rebranding is due to the need to adapt to the new environment and to transform the company itself which, in addition to carrying out oil product storage and transport activities in Spain, has embarked on an international growth process and is now present in 7 other countries. The group has expanded its activity to the storage, management and transportation of liquid products, especially chemical products, operating in new sectors, such as eco-fuels, the circular economy and the development of new energy vectors. The new name, simple but modern, shows a spirit where innovation is the key. The Exolum brand was originally devised as the CLH Group subsidiary dedicated to entrepreneurship and innovation. However, after sev

CGTN: What Are Generations of Chinese Communists Striving For?27.2.2021 18:36:00 EETPress release

The Communist Party of China (CPC), the ruling party of the world's most populous nation and the second largest economy, is turning 100 this year. What has been motivating the CPC to fight against one challenge after another over the past century? This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210227005021/en/ "The original aspiration and the mission of Chinese Communists is to seek happiness for the Chinese people and rejuvenation for the Chinese nation," General Secretary Xi Jinping of the CPC Central Committee said in his report to the 19th CPC National Congress in October 2017. "This founding aspiration, this mission, is what inspires the Chinese Communists to advance," Xi said. Self-discipline, selflessness In March 2018, Xi, also the Chinese president, further explained the cause pursued by the CPC with a quote from an ancient poem: "A virtuous person is as sharp-sighted as a clear mirror hanging high, a selfless perso

Colicity Inc. Announces Closing of $345 Million Initial Public Offering27.2.2021 01:00:00 EETPress release

Colicity Inc. (the “Company”) announced the closing today of its initial public offering of 34,500,000 units, including the underwriters’ exercise of their full over-allotment option for 4,500,000 units, at a price of $10.00 per unit. The units are listed on the NASDAQ Stock Market (NASDAQ) and began trading under the ticker symbol “COLIU” on February 24, 2021. Each unit consists of one Class A share and one-fifth of one redeemable warrant, with each whole warrant exercisable to purchase one Class A share at a price of $11.50 per share. Only whole warrants will be exercisable. Once the securities comprising the units begin separate trading, the Class A shares and warrants are expected to be listed on the NASDAQ under the symbols “COLI” and “COLIW,” respectively. Colicity Inc. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company int

C3 AI and Baker Hughes to Provide Enterprise AI Solutions to Accelerate PETRONAS Digital Transformation Program26.2.2021 17:00:00 EETPress release

C3 AI (NYSE: AI) and Baker Hughes today announced an artificial intelligence (AI) collaboration with PETRONAS, a global energy and solutions company from Malaysia, to apply BakerHughesC3.ai (BHC3) technology across PETRONAS’s strategic digital transformation programs. As the custodian of Malaysia's national oil and gas resources, PETRONAS runs an extensive digital transformation program across energy operations to extract value from data. The adoption of AI as part of its overall program for improved oil and gas productivity, asset integrity, and safety supports PETRONAS’s commitment to provide clean, efficient energy solutions by harnessing the power of technology. PETRONAS will work with energy technology, data science, and AI experts at Baker Hughes and C3 AI to collaborate on projects focused on improved reliability of energy assets in critical operations. Utilizing Microsoft Azure, PETRONAS will deploy the BHC3™ Reliability application to further improve maintenance programs for g

Avania in Position for Next Stage of Growth26.2.2021 16:00:00 EETPress release

Avania, a leading global full-service contract research organization (CRO) focused on medical technology (MedTech) development, today announced that it has successfully refinanced its existing banking facilities with Crescent Capital Group. “This new banking facility allows us to accelerate our next phase of organic and acquisitive growth over the next few years,” said Edo van Houten, CFO of Avania. “This transaction is also a reflection of the progress we have made in our brand strategy and position in the market, and it demonstrates the confidence of the financial community in our operational and strategic plan.” Avania has navigated confidently through the COVID-19 pandemic, posting a strong year of growth in 2020 despite the pandemic. The company will continue its growth trajectory as a global MedTech-focused CRO, supporting products from concept through post-market support. MedTech is all Avania does, navigating innovative medical technologies to market effectively and efficiently

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom